Recruiting PHASE1/PHASE2 INTERVENTIONAL 9-arm NCT06188702

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Sponsor: Institut de Recherches Internationales Servier

Conditions MTAP-deleted Solid Tumors

Interventions S095035 TNG462

Updated 15 times since 2024 Last updated: Mar 12, 2026 Started: Apr 29, 2024 Primary completion: Oct 31, 2031 Completion: Oct 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06188702, this PHASE1/PHASE2 trial focuses on MTAP-deleted Solid Tumors and remains actively recruiting participants. Sponsored by Institut de Recherches Internationales Servier, it has been updated 15 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

15 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 10 earlier versions

Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1 → PHASE1/PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut de Recherches Internationales Servier
Servier Bio-Innovation LLC
Tango Therapeutics, Inc.

Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Austin, United States , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Boston, United States , Copenhagen, Denmark , Dijon, France , Douglas, Australia , Durham, United States and 22 more locations